JPH04129562A - Artificial skin - Google Patents
Artificial skinInfo
- Publication number
- JPH04129562A JPH04129562A JP2247299A JP24729990A JPH04129562A JP H04129562 A JPH04129562 A JP H04129562A JP 2247299 A JP2247299 A JP 2247299A JP 24729990 A JP24729990 A JP 24729990A JP H04129562 A JPH04129562 A JP H04129562A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- collagen
- water
- film
- denatured collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010035532 Collagen Proteins 0.000 claims abstract description 46
- 102000008186 Collagen Human genes 0.000 claims abstract description 46
- 229920001436 collagen Polymers 0.000 claims abstract description 46
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 15
- 239000005017 polysaccharide Substances 0.000 claims abstract description 15
- 150000004676 glycans Chemical class 0.000 claims abstract description 8
- 210000001339 epidermal cell Anatomy 0.000 claims description 12
- 210000002950 fibroblast Anatomy 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 abstract description 9
- 239000007864 aqueous solution Substances 0.000 abstract description 7
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 4
- 229940088598 enzyme Drugs 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 abstract description 3
- 230000002378 acidificating effect Effects 0.000 abstract description 3
- 210000001124 body fluid Anatomy 0.000 abstract description 3
- 239000010839 body fluid Substances 0.000 abstract description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 abstract description 2
- 102000057297 Pepsin A Human genes 0.000 abstract description 2
- 108090000284 Pepsin A Proteins 0.000 abstract description 2
- 238000007605 air drying Methods 0.000 abstract description 2
- 230000000890 antigenic effect Effects 0.000 abstract description 2
- 229940059329 chondroitin sulfate Drugs 0.000 abstract description 2
- 238000004132 cross linking Methods 0.000 abstract description 2
- 229940111202 pepsin Drugs 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 35
- 210000001519 tissue Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 11
- 230000035699 permeability Effects 0.000 description 10
- 206010052428 Wound Diseases 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 150000004804 polysaccharides Chemical class 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 6
- 108010045569 atelocollagen Proteins 0.000 description 5
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 239000000515 collagen sponge Substances 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 229940029339 inulin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000003760 tallow Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006803 Burns third degree Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- -1 are preferred Polymers 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012668 chain scission Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、火傷の皮膚創傷等を治癒するために用いられ
る新規な人工皮膚に関する。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a novel artificial skin used for healing skin wounds such as burns.
人間の皮膚の重要な領域の創傷、特に重度の火傷の場合
に、その創傷を皮膚の機能の1部を備えた物質で被覆す
る必要がある。これらの機能とは流体損失の減少、感染
防止、および潜在的廠痕領域の減少を意味する。この問
題を解決するのに採られてきたアプローチは同種移植、
合成重合体構造物またはコラーゲンフィルムの使用を含
んでいる。患部に対する処理としては、本人の正常な部
位の皮膚をとり、自家移植することが現在最善の策とさ
れている。しかしながら、自家移植は常に適用可能であ
るとは限らず、例えば欠損部が広範にわたる場合などは
非常に困難なものとなり、適用可能である場合も一度に
すべての欠損部に移植することは不可能であり、長期間
にわたり幾度となく移植を繰り返す必要がある。このた
め自家移植に代わり患部を一時的にあるいは永続的に被
覆し、組繊細胞を増殖して組織の修復を促進するための
人工皮膚の開発が望まれている。BACKGROUND OF THE INVENTION In wounds in critical areas of human skin, especially in the case of severe burns, it is necessary to cover the wound with a substance that has some of the functions of skin. These features mean reduced fluid loss, infection prevention, and reduced potential scar area. The approach that has been taken to solve this problem is allogeneic transplantation,
Including the use of synthetic polymer structures or collagen films. Currently, the best treatment for the affected area is to take skin from a normal area of the patient and perform an autologous transplant. However, autologous transplantation is not always applicable; for example, when the defect is extensive, it becomes extremely difficult, and even when it is applicable, it is impossible to transplant to all the defects at once. Therefore, it is necessary to repeat transplantation many times over a long period of time. For this reason, there is a desire to develop artificial skin that can temporarily or permanently cover the affected area in place of autologous transplants, proliferate tissue cells, and promote tissue repair.
また、近年培養移植法あるいは培養皮膚とも言える皮膚
に近い材料の移植法が行なわれてきている。これは重度
の患者を対象として、患者の残された正常部位の皮膚を
採取して、単離した細胞を試験管内で培養を行ない、も
との細胞の数十倍から数百倍に増殖したのち、被覆膜と
ともに患者の創傷部位に移植してやり、表皮化を形成さ
せ治癒を図るものである。この方法を臨床に応用した例
として、ガリコら(G、 G、 Gatl+eo eL
at、、 )の研究にューイングランド ジャーナル
オブメディスン、第311巻、第7号、448〜45
1頁)(New Eng、 J、 Med、、 VoI
z、 311. No、 7. P、 448〜451
(1984) )がある。Furthermore, in recent years, a culture transplantation method or a method of transplanting a material similar to skin, which can be called cultured skin, has been carried out. This is aimed at severely ill patients, and the skin from the patient's remaining normal area is taken, and the isolated cells are cultured in a test tube, and the cells are multiplied tens to hundreds of times the size of the original cells. Later, it is transplanted together with a covering membrane to a patient's wound site to form epidermis and promote healing. As an example of clinical application of this method, Gallico et al.
New England Journal of Medicine, Vol. 311, No. 7, 448-45.
1 page) (New Eng, J, Med,, VoI
z, 311. No, 7. P, 448-451
(1984)).
従来、生体由来材料であるコラーゲンはスポンジまたは
フィルム状に成型して創傷被覆材として使われてきた。Conventionally, collagen, which is a bio-derived material, has been molded into a sponge or film and used as a wound dressing.
しかし、これらで火傷等を被覆した場合、早期の組織修
復が認められないという問題があった。特に、これらの
アプローチの中における重大な問題は皮膚の置換の、特
に免疫抑制剤の存在下での拒絶や宿主の酵素による移植
片の分解である。However, when burns and the like are covered with these, there is a problem in that early tissue repair is not observed. In particular, a significant problem within these approaches is rejection of skin replacement, especially in the presence of immunosuppressants, and degradation of the graft by host enzymes.
一方、コラーゲンの中に細胞を組み込む方法が行なわれ
ているが、培養直後のコラーゲンゲルの直径が60m1
あったものが、−週間経つと約IO關に収縮してしまう
為、人工皮膚として使用する場合に広範囲な熱傷に適用
することが難しい。On the other hand, a method of incorporating cells into collagen has been used, but the diameter of the collagen gel immediately after culture is 60 m1.
However, it shrinks to about IO after - weeks, making it difficult to apply to a wide range of burns when used as artificial skin.
培養表皮シートを患者の創傷部位に移植する場合、主に
真皮が残存している母殊に移植すると生むするが、全層
皮膚欠損創や三度熱傷の創面には土管することが難しい
。また、アテロコラーゲンシート上に表皮細胞を培養し
て移植した場合、コラーゲンシートが物質透過性が低い
為、十分な栄養供給がなされず、最終的に表皮細胞が死
滅してしまうなどの問題がある。When transplanting a cultured epidermal sheet to a patient's wound site, it is most likely to be transplanted to a wound site where the dermis remains, but it is difficult to transplant it to a wound with full-thickness skin loss or third-degree burns. Furthermore, when epidermal cells are cultured and transplanted onto an atelocollagen sheet, there is a problem that, because the collagen sheet has low substance permeability, sufficient nutrients are not supplied, and the epidermal cells eventually die.
本発明は上記事情に鑑み、移植者の表皮・線維芽細胞を
生体外で培養して、収縮することなく皮膚組織を形成さ
せ、火傷等の被覆(移植)において、該フィルムだけが
滲出液等の体液で分解吸収して、皮膚の再生を可能にす
る人工皮膚基材を提供することを目的とする。In view of the above circumstances, the present invention cultivates the epidermis and fibroblasts of the transplanted person in vitro to form skin tissue without shrinking, and when covering (transplanting) burns, etc., only the film can be used to eliminate exudate or the like. The purpose of the present invention is to provide an artificial skin base material that can be decomposed and absorbed by body fluids to enable skin regeneration.
本発明の上記目的は以下の構成により達成される。The above object of the present invention is achieved by the following configuration.
1)変性コラーゲンと水溶性多糖類とからなるコアセル
ベートによって形成されたフィルムからなり、該フィル
ムが架橋されていることを特徴とする人工皮膚。1) Artificial skin consisting of a film formed from coacervate made of denatured collagen and water-soluble polysaccharide, and characterized in that the film is crosslinked.
2)1項の人工皮膚の一方の面に皮膚由来の表皮細胞の
生きている組織を形成せしめた人工皮膚。2) Artificial skin in which a living tissue of skin-derived epidermal cells is formed on one side of the artificial skin of item 1.
3)コラーゲンと少なくとも5重量%の変性コラーゲン
を含む変性コラーゲンとからなるマトリックスのスポン
ジ層と、その上に積層された1項の人工皮膚とからなる
人工皮膚。3) An artificial skin comprising a sponge layer of a matrix comprising collagen and denatured collagen containing at least 5% by weight of denatured collagen, and the artificial skin of item 1 laminated thereon.
4)3項の人工皮膚の、前記コアセルベートからなるフ
ィルム上に皮膚由来の表皮細胞の生きている組織を形成
せしめ、前記スポンジ層に皮膚由来の線維芽細胞の生き
ている組織を形成せしめた人工皮膚。4) An artificial skin according to item 3, in which a living tissue of skin-derived epidermal cells is formed on the film made of the coacervate, and a living tissue of skin-derived fibroblasts is formed on the sponge layer. Skin.
本発明における変性コラーゲンは牛真皮由来のコラーゲ
ンをプロクターゼまたはペプシン等の酵素で消化処理し
て抗原話テロペプチドを除去してアテロコラーゲンとし
、更にこれを37〜90℃の温度に加熱して変性させた
ものが望ましい。The denatured collagen in the present invention is obtained by digesting collagen derived from bovine dermis with enzymes such as proctase or pepsin to remove antigenic telopeptides to obtain atelocollagen, which is then heated to a temperature of 37 to 90°C to denature it. Something is desirable.
この熱変性条件が多糖類とのコアセルベート形成に非常
に影響する。食性温度と嚢性処理時間の程度により、コ
ラーゲン分子−のらせん繊維(ヘリックス)の巻き戻し
の程度、pH変化に対する反応性等が異なる。そのため
に、変性の程度を調整して、水溶性多糖類希薄水溶液と
混合したときに、適切にコアセルベートを形成するよう
にすることができる。コラーゲンは、37℃が熱変性温
度であり、37℃以上の温度をかけると、コラーゲン特
有の3水路らせん構造を失い、構造が変化する。分子鎖
切断を伴わない立体構造の全面的なランダム化も重要因
子であると思われる。好適な加熱変性処理は60℃で3
0分処理であり、この処理を行なうと変性コラーゲンの
へリックス含量は約40%である。This thermal denaturation condition greatly influences coacervate formation with polysaccharides. The degree of unwinding of the helical fibers (helices) of collagen molecules, the reactivity to pH changes, etc. differ depending on the feeding temperature and the degree of cystic treatment time. For this purpose, the degree of denaturation can be adjusted so that a coacervate is appropriately formed when mixed with a dilute aqueous solution of a water-soluble polysaccharide. Collagen has a thermal denaturation temperature of 37°C, and when a temperature of 37°C or higher is applied, the three-channel helical structure unique to collagen is lost and the structure changes. Complete randomization of the three-dimensional structure without chain scission also appears to be an important factor. A suitable heat denaturation treatment is 3 at 60°C.
This is a 0 minute treatment, and when this treatment is performed, the helix content of the denatured collagen is about 40%.
水溶性多糖類は多糖類のうち、水によく溶ける多糖類を
意味し、ムコ多糖類、特にコンドロイチン硫酸、ヘパラ
ン硫酸、デルマタン硫酸、ヒアルロン酸、ヘパリンのよ
うな酸性ムコ多糖類が望ましく、アルギン酸も好適に使
用される。Water-soluble polysaccharides refer to polysaccharides that dissolve well in water, and mucopolysaccharides, particularly acidic mucopolysaccharides such as chondroitin sulfate, heparan sulfate, dermatan sulfate, hyaluronic acid, and heparin, are preferred, and alginic acid is also preferred. Preferably used.
変性コラーゲンと水溶性多糖類からなるコアセルベート
は常法に従って製造される。即ち、変性コラーゲン水溶
液と水溶性多糖類水溶液を、変性コラーゲン1重量部に
対して水溶性多糖類0.05〜1重全部の割合で混合し
、塩酸等を用いてpHを酸性に調整し、白濁した溶液を
クリーンベンチ内で風乾することによって得られる。Coacervate consisting of denatured collagen and water-soluble polysaccharide is produced according to a conventional method. That is, a denatured collagen aqueous solution and a water-soluble polysaccharide aqueous solution are mixed at a ratio of 0.05 to 1 part by weight of the water-soluble polysaccharide per 1 part by weight of the denatured collagen, and the pH is adjusted to acidic using hydrochloric acid or the like. Obtained by air-drying a cloudy solution in a clean bench.
人工皮膚作製するに隙し、コアセルベートからなるフィ
ルムはコラゲナーゼなどの酵素による分解を抑制するた
めに、真空下で110〜180℃の範囲、好ましくは1
40〜160℃の範囲内で24時間以上熱脱水架橋する
ことが好ましい。この条件下で処理したフィルムは表皮
細胞を培養している際には分解しないが、移植した場合
には滲出液他の体液ですみやかに分解吸収される。In order to prevent the production of artificial skin from being degraded by enzymes such as collagenase, the film made of coacervate is heated under vacuum at a temperature in the range of 110 to 180°C, preferably 1.
It is preferable to carry out thermal dehydration crosslinking within the range of 40 to 160°C for 24 hours or more. Films treated under these conditions do not decompose while culturing epidermal cells, but when transplanted, they are quickly decomposed and absorbed by exudate and other body fluids.
またコアセルベートフィルムは表皮細胞を培養する際、
培地からの栄養分の供給などを考慮して、多孔性にして
通気性を持たせることが好ましい。コアセルベートから
なるフィルムはグルコース(M−180)、ビタミンB
12(M−H55) 、イヌリンCM = 5200)
のような溶質を透過することができる。In addition, coacervate film is used when culturing epidermal cells.
In consideration of the supply of nutrients from the culture medium, it is preferable to make it porous and provide air permeability. The film made of coacervate contains glucose (M-180) and vitamin B.
12 (M-H55), inulin CM = 5200)
can pass through solutes such as
コアセルベートからなるフィルムの厚さは、コラーゲン
溶液の濃度と容量により調製することができる。膜厚は
溶質の透過性との関連より約5〜100ρが好ましく、
より好ましくは約10〜50t1mである。The thickness of the coacervate film can be adjusted by adjusting the concentration and volume of the collagen solution. The film thickness is preferably about 5 to 100 ρ in relation to solute permeability.
More preferably, it is about 10 to 50 t1m.
コラーゲン・変性コラーゲンマトリックスは上記で調製
した線維化したコラーゲン溶液と変性コラーゲン8液を
混合して、凍結乾燥して得ることができる。この際に、
スチレン容器内に混合溶液を流し込み、その上に上記の
変性コラーゲンフィルムをのせ、凍結乾燥するとフィル
ムがラミネートしたコラーゲン・変性コラーゲンのマト
リックスが得られる。Collagen/denatured collagen matrix can be obtained by mixing the fibrotic collagen solution prepared above and 8 liquids of denatured collagen, and freeze-drying the mixture. At this time,
The mixed solution is poured into a styrene container, the above-mentioned denatured collagen film is placed thereon, and the denatured collagen film is lyophilized to obtain a collagen/denatured collagen matrix laminated with the film.
人工皮膚を作製するには、まず移植すべき患者の一部を
デルマトームで剥離し、表皮と真皮に分け、更に表皮基
底細胞を上記で得られたコアセルベートフィルムに接触
させ、コラーゲンスポンジには線維芽細胞を接触させ、
生理的条件下で維持することによって人工皮膚が得られ
る。To create artificial skin, first remove the part of the patient to be transplanted using a dermatome, separate it into the epidermis and dermis, then bring the epidermal basal cells into contact with the coacervate film obtained above, and add fibroblasts to the collagen sponge. contact the cells,
Artificial skin is obtained by maintaining it under physiological conditions.
こ°の一連の操作は細胞を取り扱った経験のある専門家
にとっては日常的な実験のみによって行なうことができ
る。This series of operations can be performed by experts with experience in handling cells using only routine experiments.
〔実 施 例〕
以下、実施例を示して本発明をさらに具体的に説明する
。[Examples] Hereinafter, the present invention will be explained in more detail with reference to Examples.
[実 施 例]
〈コアセルベートの作製〉
アテロコラーゲンを0.3(v/v)%となるように蒸
留水で膨潤させてアテロコラーゲン溶液とし、この水溶
液を室温になじませた後、60℃に保ったオーブン内に
て約2時間加熱操作を行ない変性コラーゲンを得る。こ
の変性コラーゲンは変性温度(37℃)以上に保ってお
く。なおこの処理温度時間で得られた変性コラーゲンは
冷却後にヘリックス構造の一定の割合で再生できる範囲
内のものである。このように得られた変性コラーゲンの
へリックス含量は約40%であった。一方、コンドロイ
チン−6−硫酸を1(ν/V)%となるように蒸留水に
溶かしコンドロイチン−6−硫酸水溶液とする。なおコ
ンドロイチン−6−硫酸として得られているものは水に
溶解後隅イオン交換樹脂でNa部分をH+型に置換して
おく。混合する際に、物質総量に対するコンドロイチン
−6−硫酸の仕込み皿は5 (v/v)%以上50 (
v/v)%以下であるが、好ましくは10(v/w)%
以上30(v/v)%以下である。[Example] <Preparation of coacervate> Atelocollagen was swollen with distilled water to a concentration of 0.3 (v/v)% to obtain an atelocollagen solution. After this aqueous solution was allowed to warm to room temperature, it was kept at 60°C. A heating operation is performed in an oven for about 2 hours to obtain denatured collagen. This denatured collagen is kept above the denaturation temperature (37°C). Note that the denatured collagen obtained at this treatment temperature and time is within the range in which the helical structure can be regenerated at a certain rate after cooling. The helix content of the denatured collagen thus obtained was about 40%. On the other hand, chondroitin-6-sulfuric acid is dissolved in distilled water to give a chondroitin-6-sulfuric acid aqueous solution to a concentration of 1 (v/V)%. In addition, what is obtained as chondroitin-6-sulfuric acid is dissolved in water, and then the Na portion is replaced with an H+ type using an ion exchange resin. When mixing, the amount of chondroitin-6-sulfate added to the total amount of substances should be 5 (v/v)% or more.
v/v)% or less, preferably 10(v/w)%
30 (v/v)% or less.
この範囲内でコアセルベートの最大収量を期待できる。Maximum yield of coacervate can be expected within this range.
混合後1規定のHCj)を用いてpl+調整をする。After mixing, adjust pl+ using 1N HCj).
pHの下降状態に応じて白濁を生じコアセルベート液滴
が形成される。この溶液をクリーンベンチ内で風乾して
乾固させた。As the pH decreases, cloudiness occurs and coacervate droplets are formed. This solution was air-dried to dryness in a clean bench.
上記で得られたフィルムを真空下で1時間真空にし、更
に140℃に温度を上げ、24時間真空に保ち、その後
温度を下げ試料を取り出した。The film obtained above was evacuated under vacuum for 1 hour, the temperature was further raised to 140°C, and the vacuum was kept for 24 hours, after which the temperature was lowered and the sample was taken out.
〈コアセルベートフィルムの透過性試験〉上記で得られ
たコアセルベートフィルムの溶質透過性評価を行なった
。膜厚20μto、 30m、及び5011mの市販の
透析セルを用いて、グルコース(分子量+ 180)、
ビタミンB12(分子m : 1355) 、イヌリン
(分子量: 5200)の透過性を調べた。第1〜第3
図は各種の溶質の透過性試験の結果である。<Permeability test of coacervate film> The solute permeability of the coacervate film obtained above was evaluated. Glucose (molecular weight + 180),
The permeability of vitamin B12 (molecular weight: 1355) and inulin (molecular weight: 5200) was investigated. 1st to 3rd
The figure shows the results of permeability tests for various solutes.
〈コアセルベートをラミネートシたコラーゲン・変性コ
ラーゲンスポンジの作製〉
o、a(v/v)%アテロコラーゲン溶液とりん酸緩衝
液(45+aM Na2HPO4,+50a+M Na
Cl1)を1=2の割合で混ぜ、これを37℃で4時間
インキュベートした。次にこの溶液を5000r、p、
a+、でlO分遠心分離後、沈殿物を1 (w/v)%
の濃度になるように調製し、これを上記で調製した変性
コラーゲンを混合した。更にスチレン製の容器に線維化
コラーゲン・変性コラーゲン混合溶液を流し込み、その
上に上記で調製したコアセルベートフィルムをのせ、−
30℃で凍結させ、凍結乾燥を行なった。<Preparation of collagen/denatured collagen sponge laminated with coacervate> o, a (v/v)% atelocollagen solution and phosphate buffer (45+aM Na2HPO4, +50a+M Na
Cl1) were mixed at a ratio of 1=2, and this was incubated at 37°C for 4 hours. Next, add this solution to 5000r, p.
After centrifugation for 10 minutes at a+, the precipitate was reduced to 1 (w/v)%
This was mixed with the denatured collagen prepared above. Furthermore, pour the fibrotic collagen/denatured collagen mixed solution into a styrene container, place the coacervate film prepared above on top of it, and -
It was frozen at 30°C and freeze-dried.
く生きた組織の形成〉
(+) 上記で作製したコアセルベートフィルムを2
e+nX2cmの大きさに切断し、これを60關シヤー
レにコアセルベートフィルムを置いた。次にラット皮膚
より採取した表皮細胞を] Xl07cells/ml
の濃度(10%牛脂児血清を含むDME培地に懸濁)で
1 ml採取し、更に37℃で3日間培養した。Formation of a living tissue〉 (+) The coacervate film prepared above was
It was cut into a size of e+n x 2 cm, and a coacervate film was placed on a 60-inch shear plate. Next, epidermal cells collected from rat skin]
(suspended in DME medium containing 10% tallow serum) and cultured at 37°C for 3 days.
上記で細胞を採取したラットの背に2cmX2c+nの
欠損創をつくり、そこに上記で得られた生きた組織を移
植した。この生きた組織は移植後1週間以内でコアセル
ベートフィルムが分解して、表皮が直接母体と接して、
生着したことが認められた。A defective wound measuring 2 cm x 2c+n was created on the back of the rat from which the cells were collected above, and the living tissue obtained above was transplanted thereto. In this living tissue, the coacervate film decomposes within one week after transplantation, and the epidermis comes into direct contact with the mother's body.
It was confirmed that the tumor had survived.
(2)上記で作製したコアセルベートフィルム・コラー
ゲン−変性コラーゲンスポンジを2CI11×2cmの
大きさに切断し、これを(10+uシヤーレにコアセル
ベートフィルムが下側になるように置いた。(2) The coacervate film/collagen-denatured collagen sponge prepared above was cut into a size of 2CI11 x 2 cm, and placed on a (10+U shear plate with the coacervate film facing down).
次にラット皮膚より採取した線維芽細胞lXl06ce
lls/ml (10%牛脂児血清を含むDME培地に
懸濁した)の濃度に調製し、コアセルベート上に1ml
播種した。更にスポンジのまわりに培養液を3ml注入
し、37℃で3日培養した。次にこのスポンジを裏返し
、コアセルベートフィルムが上になるように置き、この
上にラット皮膚より採取した表皮細胞をI X 107
eel Is/ mlの濃度(10%牛脂児血清を含む
DME培地に懸濁)で1ml採取し、さらに37℃で3
日間培養した。Next, fibroblasts lXl06ce collected from rat skin
lls/ml (suspended in DME medium containing 10% tallow serum) and 1 ml onto the coacervate.
Sowed. Furthermore, 3 ml of culture solution was injected around the sponge and cultured at 37°C for 3 days. Next, turn this sponge over so that the coacervate film is facing up, and place the epidermal cells collected from rat skin on top of it.
Collect 1 ml of eel Is/ml (suspended in DME medium containing 10% tallow serum) and further incubate at 37°C for 3
Cultured for 1 day.
上記で細胞を採取したラットの背に2cmX2cmの欠
損創をつくり、そこに上記で得られた生きた組織を移植
した。この生きた組織は移植後すぐに生着し、移植7日
目の組織病理像では皮膚組織と同様なものが構築されつ
つあることが認められた。A 2 cm x 2 cm defective wound was created on the back of the rat from which the cells were collected above, and the living tissue obtained above was transplanted thereto. This living tissue took root immediately after transplantation, and histopathological images on the 7th day of transplantation showed that something similar to skin tissue was being constructed.
本発明は変性コラーゲンと水溶性多糖類との混lがコア
セルベート構造を形成したフィルムに、皮膚構成細胞で
ある表皮細胞を組み込み、それらを生理的条件下で維持
することにより、生体外において生きた皮膚組織を形成
することを可能とするものである。この生きた組織を皮
膚欠損部へ移植すると、治癒過程を著しく短縮すること
ができる。The present invention incorporates epidermal cells, which are skin constituent cells, into a film in which a mixture of denatured collagen and water-soluble polysaccharide forms a coacervate structure, and maintains them under physiological conditions to make them viable in vitro. It makes it possible to form skin tissue. Transplanting this living tissue into skin defects can significantly speed up the healing process.
さらに、本発明はコアセルベートフィルムと変性コラー
ゲン・コラーゲンスポンジ層を組み合せたマトリックス
に、皮膚構成細胞である表皮細胞と線維芽細胞を組み込
み、それらを生理的条件下で維持することにより、生体
外において生きた皮膚組織を形成することを可能とする
ものである。Furthermore, the present invention incorporates epidermal cells and fibroblasts, which are skin constituent cells, into a matrix that combines a coacervate film and a denatured collagen/collagen sponge layer, and maintains them under physiological conditions to survive in vitro. This makes it possible to form a skin tissue that has a unique structure.
この生きた組織を皮膚欠損部へ移植するとある程度の組
織構築がなされているため、治癒過程を著しく短縮する
ことができる。When this living tissue is transplanted into the skin defect, a certain amount of tissue structure has been achieved, so the healing process can be significantly shortened.
第1図はコアセルベートフィルムのグルコース透過性を
示す。
第2図はコアセルベートフィルムのビタミンB1□透過
性を示す。
第3図はコアセルベートフィルムのイヌリン透過性を示
す。
第1図ないし第3図において、コアセルベートの膜厚は
Oは20B 、△は30.IZll、口は5o−を示す
。
ロ寺
問
(hr)
第
図
時
間
(h r)
第
図FIG. 1 shows the glucose permeability of coacervate films. Figure 2 shows the vitamin B1□ permeability of coacervate films. Figure 3 shows the inulin permeability of coacervate films. In FIGS. 1 to 3, the thickness of the coacervate is 20B for O and 30B for Δ. IZll, mouth indicates 5o-. Time (hr) Fig. Time (hr) Fig.
Claims (1)
ベートによって形成されたフィルムからなり、該フィル
ムが架橋されていることを特徴とする人工皮膚。 2)請求項1の人工皮膚の一方の面に皮膚由来の表皮細
胞の生きている組織を形成せしめた人工皮膚。 3)コラーゲンと少なくとも5重量%の変性コラーゲン
を含む変性コラーゲンとからなるマトリックスのスポン
ジ層と、その上に積層された請求項1の人工皮膚とから
なる人工皮膚。 4)請求項3(7)人工皮膚の、前記コアセルベートか
らなるフィルム上に皮膚由来の表皮細胞の生きている組
織を形成せしめ、前記スポンジ層に皮膚由来の線維芽細
胞の生きている組織を形成せしめた人工皮膚。[Scope of Claims] 1) An artificial skin comprising a film formed from a coacervate made of denatured collagen and a water-soluble polysaccharide, the film being crosslinked. 2) An artificial skin in which a living tissue of skin-derived epidermal cells is formed on one side of the artificial skin of claim 1. 3) An artificial skin comprising a matrix sponge layer comprising collagen and denatured collagen containing at least 5% by weight of denatured collagen, and the artificial skin of claim 1 laminated thereon. 4) Claim 3 (7) Forming a living tissue of skin-derived epidermal cells on the film made of the coacervate of the artificial skin, and forming a living tissue of skin-derived fibroblasts on the sponge layer. Tightened artificial skin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2247299A JPH04129562A (en) | 1990-09-19 | 1990-09-19 | Artificial skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2247299A JPH04129562A (en) | 1990-09-19 | 1990-09-19 | Artificial skin |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH04129562A true JPH04129562A (en) | 1992-04-30 |
Family
ID=17161363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2247299A Pending JPH04129562A (en) | 1990-09-19 | 1990-09-19 | Artificial skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH04129562A (en) |
-
1990
- 1990-09-19 JP JP2247299A patent/JPH04129562A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4883487A (en) | Method of producing an artifical skin | |
JP5689023B2 (en) | Surgical device for skin treatment or examination | |
JP2820796B2 (en) | Biotherapeutic cell-coated microspheres | |
JPH05506169A (en) | Synthetic biological skin equivalent | |
CN100400655C (en) | Engineered extracellular matrix preparation method | |
JPH11503946A (en) | Artificial skin containing a biocompatible substance based on a hyaluronic acid derivative as a support | |
Wheeler Jr et al. | Epidermal-dermal interactions in adult human skin. II. The nature of the dermal influence | |
CN101773687B (en) | Preparation method of composite soft-tissue patch | |
JP2858066B2 (en) | Tissue culture method and culture substrate used for it | |
KR100520944B1 (en) | Collagen-based supports for tissue engineering and manufacture of biomaterials | |
Vaienti et al. | Limb trauma: the use of an advanced wound care device in the treatment of full-thickness wounds | |
CN113082286A (en) | Three-layer bionic skin stent based on 3D printing technology and preparation method thereof | |
US20170368231A1 (en) | Bioengineered Regenerative Graft Matrix, and Methods for Making Thereof | |
CN100402097C (en) | Skin wound repairing agar/collagen dressing and its prepn and application | |
CN110841104B (en) | Preparation method of salidroside-collagen sponge scaffold and application of salidroside-collagen sponge scaffold in skin wound repair | |
WO2003094985A1 (en) | Artificial extracellular matrix and process for producing the same | |
JPH04129562A (en) | Artificial skin | |
JPH04129563A (en) | Artificial skin and its manufacture | |
RU2644306C1 (en) | Method of recovery of defects of covering tissues | |
JP3105308B2 (en) | Artificial skin and method for producing the same | |
JPS6141452A (en) | Artificial skin | |
JPH0271749A (en) | Artificial skin | |
CN116036355B (en) | Human fat extracellular matrix membrane and preparation method and application thereof | |
CN1737129B (en) | Artificial skin transplant and its preparation method | |
JPH04332561A (en) | Matrix for culture skin |